Compare Aurora Cannabis Inc (ACB) vs Ross Stores, Inc. (ROST) Price & Performance

Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.

ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.

Ross Stores (ROST) trades at $255.23, up 0.36% on the day, near its consensus price target of $259. The stock shows strong momentum with a bullish technical signal and consistent earnings beats, including Q1 2026 EPS of $2.02 versus $1.73 expected. Revenue growth accelerated to $21.13B in 2025, with net income margin improving to 9.74%. Recent expansion includes 47 new stores opened in June-July 2026, supporting future growth.

Outlook remains positive given robust fundamentals and analyst optimism, but valuation multiples like P/E of 35.65 suggest premium pricing. Key risks include consumer spending sensitivity and competitive pressures in discount retail. The stock offers growth potential with disciplined execution, though investors should weigh high valuation against earnings sustainability.